Dar Al Dawa Development & Investment operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Dar Al Dawa Development & Investment with three other
pharmaceutical manufacturers in Middle East:
Memphis Pharmaceutical & Chemical Industries
sales of 396.15 million Egyptian Pounds [US$44.61 million]
(195.82 million Israel Shekels [US$51.05 million]
of which 107%
was Nutrition), and
Glaxo Smith Kline
based in Egypt
(1.02 billion Egyptian Pounds [US$114.97 million]
of which 100%
was Pharmaceutical Products).
Dar Al Dawa Development & Investment reported sales of 62.14 million Jordanian Dinars (US$87.77 million)
December of 2015.
decrease of 9.9%
versus 2014, when the company's sales were 68.97 million Jordanian Dinars.
Contributing to the drop in overall sales was the 12.0% decline
in Pharmaceuticals, from 55.17 million Jordanian Dinars to 48.57 million Jordanian Dinars.
There were also decreases in sales in
Infant Food and Milk (down 1.7% to 13.56 million Jordanian Dinars)